Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in fatty liver shionogi mouse

Hepatology Research

Volumn 44, Issue 1, 2014, Pages 102-113

  Wang, Xiang ^a   Sugimoto, Ken ^a   Fujisawa, Tomomi ^b   Shindo, Nobuyasu ^a   Minato, Satomi ^a   Kamada, Yoshihiro ^a   Hamano, Mina ^a   Ohishi, Mitsuru ^a   Ikegami, Hiroshi ^c   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sakai City Medical Center   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ezetimibe; Microsomal triglyceride transfer protein; Non alcoholic fatty liver disease; Reactive oxygen species

Indexed keywords

BETA ACTIN; CELL CYCLE PROTEIN 20; EZETIMIBE; LIPID; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; REACTIVE OXYGEN METABOLITE; S PHASE KINASE ASSOCIATED PROTEIN 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FATTY LIVER SHIONOGI MOUSE; LIPOGENESIS; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; MOUSE; MOUSE STRAIN; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TREATMENT DURATION; UBIQUITINATION;

EID: 84891820153     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12092     Document Type: Article

References (30)

1. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589.
2. Chitturi S, Abeygunasekera S, Farrell GC etal. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
4. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1-16.
5. Soga M, Kishimoto Y, Kawaguchi J etal. The FLS mouse: a new inbred strain with spontaneous fatty liver. Lab Anim Sci 1999; 49: 269-275.
6. Harano Y, Yasui K, Toyama T etal. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006; 26: 613-620.
7. Oze-Fukai A, Fujisawa T, Sugimoto K etal. A novel mouse model for type 2 diabetes and non-alcoholic fatty liver disease: spontaneous amelioration of diabetes by augmented beta cell mass. Endocr J 2009; 56: 227-234.
8. Shindo N, Fujisawa T, Sugimoto K etal. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J Hepatol 2010; 52: 903-912.
9. Fujita K, Nozaki Y, Wada K etal. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009; 50: 772-780.
10. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 2007; 45: 1097-1107.
11. Fujita K, Imajo K, Shinohara Y etal. Novel findings for the development of drug therapy for various liver diseases: liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis. J Pharmacol Sci 2011; 115: 270-273.
12. Altmann SW, Davis HR Jr, Zhu LJ etal. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-1204.
13. Zheng S, Hoos L, Cook J etal. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008; 584: 118-124.
14. Matono T, Koda M, Tokunaga S etal. Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice. Hepatol Res 2011; 41: 1240-1248.
15. Nozaki Y, Fujita K, Yoneda M etal. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-556.
16. Yoneda M, Fujita K, Imajo K etal. Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis. J Gastroenterol 2011; 46: 415-416.
17. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
18. Rava P, Athar H, Johnson C, Hussain MM. Transfer of cholesteryl esters and phospholipids as well as net deposition by microsomal triglyceride transfer protein. J Lipid Res 2005; 46: 1779-1785.
19. Pan X, Hussain FN, Iqbal J, Feuerman MH, Hussain MM. Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis. J Biol Chem 2007; 282: 17078-17089.
20. Muraoka T, Aoki K, Iwasaki T etal. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metab Clin Exp 2011; 60: 617-628.
21. Pereira IV, Stefano JT, Oliveira CP. Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2011; 5: 245-251.
22. Sato R. [Sterol regulatory element binding protein that controls cholesterol metabolism]. Nihon Rinsho 1999; 57: 2678-2683.
23. Li Y, Xu S, Mihaylova MM etal. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376-388.
24. Repa JJ, Turley SD, Quan G, Dietschy JM. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res 2005; 46: 779-789.
25. Reed SI. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol 2003; 4: 855-864.
26. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 2004; 5: 739-751.
27. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
28. Ohta Y, Kongo-Nishimura M, Matsura T, Yamada K, Kitagawa A, Kishikawa T. Melatonin prevents disruption of hepatic reactive oxygen species metabolism in rats treated with carbon tetrachloride. J Pineal Res 2004; 36: 10-17.
29. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1030-1038.
30. Lee SB, Kim JJ, Chung JS etal. Romo1 is a negative-feedback regulator of Myc. J Cell Sci 2011; 124: 1911-1924.